“Intentional effort” needed from sponsors to achieve diversity in oncology clinical trials
Representatives from the biopharma industry agreed that “intentional effort” is required from sponsors to ensure diverse populations are reached in …
World Immunization Week 2024: mRNA vaccines hold potential in multiple disease areas
World Immunization Week occurs annually during the last week of April. The campaign aims to highlight the collective action needed …
Alto Neuroscience reveals positive ALTO-101 Phase I trial results
Alto Neuroscience has reported positive results from its Phase I clinical trial of the PDE4 inhibitor, ALTO-101, for treating cognitive …
Response Pharmaceuticals’ RDX-002 meets primary endpoint in Phase Ib trial
Response Pharmaceuticals announced that the Phase Ib clinical trial yielded positive results for RDX-002, a novel treatment aimed at preventing …
Novartis and MMV’s Coartem shows promise in infants with Phase II/III data
Novartis and Medicines for Malaria Venture (MMV) have reported positive data from the Phase II/III CALINA trial of Coartem (artemether …
Alzheimer’s trial doses patients with stem cell treatment directly to brain
California-based Regeneration Biomedical has dosed the first patient has been dosed in a first-in-human trial of its autologous stem cell …
Neurocrine reports positive Phase II trial results for NBI-1065845
Neurocrine Biosciences has announced positive topline data from its Phase II SAVITRI study, evaluating the efficacy and safety of NBI-1065845 …
Hanmi signs clinical trial collaboration with MSD
South Korea-based Hanmi Pharmaceutical has signed a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & …
Hepion shelves Phase II NASH trial amid shallow cash resources
Hepion Pharmaceuticals has called it quits on a Phase IIb trial investigating the biotech’s lead drug candidate for the treatment …
Interim analysis of APPLAUSE-IgAN trial sheds positive light on Fabhalta for IgAN
At this year’s World Congress of Nephrology, positive results were presented from Novartis’s pre-specified interim analysis of the Phase III …
Krystal Biotech doses first subject in lung cancer drug trial
US-based biotechnology company Krystal Biotech has dosed the first subject in the Phase I KYANITE-1 clinical trial for its inhaled …
ASLAN reports interim data from atopic dermatitis drug trial
Singapore-based biopharmaceutical company ASLAN Pharmaceuticals has announced positive interim data from its Phase II TREK-DX study of eblasakimab, a drug …
Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint
Sanofi’s rilzabrutinib has found success and met the primary endpoint in the Phase III LUNA trial in heavily pre-treated immune …
Actinogen finishes enrolling patients in depression therapy trial
Australian biotechnology company Actinogen Medical has finished enrolling subjects in the Phase IIa XanaCIDD clinical trial of Xanamem for treating …
Lantern Pharma cleared to expand lung cancer treatment trial
US-based biopharmaceutical company Lantern Pharma has received regulatory approval for expanding its Phase II Harmonic clinical trial of an investigational …